Mihir Parikh, MD
Ophthalmology · la Jolla, CANPI 1740392695
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.2%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Ocular Therapeutix, Inc. at 36.3% of the total. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 424 payments — averaging $190.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$29K
- Oasis Medical, Inc.$15K
- Bausch & Lomb Americas Inc.$15K
- Sun Pharmaceutical Industries Inc.$8K
- Alcon$3K
- Glaukos Corporation$3K
- plus $8K from 28 others
What the payments were for
- Consulting fees$27,45034%
- Speaking & faculty fees$38,20747%
- Travel & lodging$2,2793%
- Food & beverage$12,89416%
- Entertainment$130%
- Other$480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 118 | $29,325 |
| Oasis Medical, Inc. | 8 | $14,750 |
| Bausch & Lomb Americas Inc. | 48 | $14,515 |
| Sun Pharmaceutical Industries Inc. | 17 | $8,386 |
| Alcon | 90 | $3,358 |
| Glaukos Corporation | 16 | $2,777 |
| Optovue, Inc. | 2 | $2,546 |
| Dompe US, Inc. | 13 | $698 |
| Rxsight Inc | 6 | $535 |
| Coopervision Inc. | 6 | $529 |
| Kala Pharmaceuticals, Inc. | 17 | $459 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $444 |
| Eyevance Pharmaceuticals LLC | 14 | $403 |
| AbbVie(2 entities) | 6 | $387 |
| Heru, Inc. | 2 | $252 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $227 |
| Tarsus Pharmaceuticals, Inc. | 6 | $188 |
| Harrow Eye, LLC | 5 | $148 |
| Sight Sciences, Inc. | 5 | $131 |
| Aerie Pharmaceuticals, Inc. | 1 | $122 |
| Boston Scientific | 1 | $117 |
| GSK | 2 | $115 |
| Novartis | 6 | $106 |
| Shire North American Group Inc | 4 | $72 |
| Staar Surgical Company | 1 | $60 |
| Oyster Point Pharma, Inc. | 2 | $57 |
| Intuitive Surgical | 1 | $50 |
| Rayner Intraocular Lenses Limited | 1 | $26 |
| Thea Pharma Inc. | 1 | $23 |
| Santen Inc. | 1 | $22 |
| Ziemer USA | 1 | $21 |
| Lumibird Medical Inc. | 1 | $17 |
| Optos, Inc. | 1 | $13 |
| Biotissue Holdings Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXTENZA$28,201
- CEQUA$8,094
- OASIS TEARS$4,375
- AngioVue$2,500
- KXL System$1,008
- Wavelight Refractive Suite$958
- INFUSE$515
- Clareon$413
- Oxervate$332
- WaveLight EX500 Excimer Laser$324
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$246
- Heru HMD$220
- Flarex$151
- XEN$144
- INVELTYS$131
- EYSUVIS$131
- STELLARIS$128
- AcrySof IQ PanOptix$125
- Rhopressa$122
- Rocklatan$122
How this compares
$80,891 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 13 | $21,894 |
| ProlensaBromfenac Sodium | 21 | $7,249 |
| Bromfenac Sodium | 31 | $4,586 |
| Prednisolone Acetate | 22 | $526 |
| Latanoprost | 21 | $349 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $14,515 | $21,89413 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $444 | $7,24921 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in la Jolla
- Quang Nguyenla Jolla$608K
- Nikolas Londonla Jolla$440K
- Tomas Grippola Jolla$427K
- Don Kikkawala Jolla$350K
- Bobby Kornla Jolla$251K
- Natalie Afsharila Jolla$205K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.